APA (7th ed.) Citation

CG, L., M, R., A, P., N, R., M, R., M, P., . . . J, B. (2024). Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma. Frontiers in pharmacology, 14, 1354581. https://doi.org/10.3389/fphar.2023.1354581

Chicago Style (17th ed.) Citation

CG, Leineweber, et al. "Corrigendum: Sorafenib Increases Cytochrome P450 Lipid Metabolites in Patient with Hepatocellular Carcinoma." Frontiers in Pharmacology 14 (2024): 1354581. https://doi.org/10.3389/fphar.2023.1354581.

MLA (9th ed.) Citation

CG, Leineweber, et al. "Corrigendum: Sorafenib Increases Cytochrome P450 Lipid Metabolites in Patient with Hepatocellular Carcinoma." Frontiers in Pharmacology, vol. 14, 2024, p. 1354581, https://doi.org/10.3389/fphar.2023.1354581.